Researchers with the James P. Allison Institute™ at The University of Texas MD Anderson Cancer Center have discovered a new ...

Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: 10-Year Outcomes of the FLAME Trial This open-label, 2-cohort, phase II trial ...

Nivolumab and ipilimumab combination approved for microsatellite instability-high or mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC), showing significant progression-free ...

Previous results from this trial showed longer overall survival after treatment with nivolumab plus ipilimumab or with nivolumab monotherapy than with ipilimumab monotherapy in patients with advanced ...

Dual anti-PD1/CTLA-4 therapy with nivolumab plus ipilimumab appears more effective than monotherapy for select patients with mCRPC, but the combination is associated with high toxicity. Dual PD1 and ...

The FDA approved nivolumab and ipilimumab for unresectable or metastatic hepatocellular carcinoma, a prevalent and deadly liver cancer in the U.S. CHECKMATE-9DW trial results showed improved median ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...